Stada Arz posts flat 3rd-qtr sales and profits downturn

14 November 2016

German drugmaker Stada Arzneimittel (SAZ: Xetra) has reported third-quarter 2016 financial results showing that group sales of 507.0 million euros ($552 million) were at around the level of the corresponding period of the previous year. Adjusted for currency and portfolio effects, adjusted group sales in this period increased slightly by 0.6% to 507.4 million euros.

In the third quarter of 2016, reported operating profit declined by 46% to 36.7 million euros. Adjusted operating profit fell 9% to 72.4 million euros.

In the third quarter of 2016, the reported earnings before interest, taxes, depreciation and amortization (EBITDA) declined by 11 to 88.4 million euros. Adjusted EBITDA decreased by 6% to  98.3 million euros.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK